TAMPA GENERAL HOSPITAL
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Intraoperative Warming: Comparison of Two Temperature Management Systems
- Conditions
- NormothermiaIntraoperative TemperatureAnesthesia
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Tampa General Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06597214
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
NCAMR-CAMR Allosure Study
- Conditions
- Transplant Failure
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Tampa General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04217343
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
Emergency Department MCG for Suspected Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Tampa General Hospital
- Registration Number
- NCT02699788
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
- Conditions
- Lung Transplantation
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Tampa General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT02177916
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Tampa General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT02167009
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Fidaxomicin Demonstrates Superior Efficacy in Reducing C. difficile Recurrence Among High-Risk Patients
Multiple studies presented at MAD-ID 2025 demonstrate fidaxomicin's superior efficacy over vancomycin in preventing C. difficile infection recurrence among high-risk patient populations.
New Transcatheter Tricuspid Valve Treatments Offer Hope for High-Risk Cardiac Patients
Innovative catheter-based treatments for tricuspid regurgitation are providing new options for patients deemed too high-risk for traditional open-heart surgery, with procedures allowing discharge within 2-3 days.
Study Reveals Gender Gap in Post-Stroke Cardiac Care: Women Receive Less Monitoring and Fewer Cardiology Referrals
New research from the DiVERT Stroke clinical study shows women experiencing stroke receive significantly fewer cardiology referrals and shorter hospital stays compared to men.
Advancements in NSCLC Treatment: Amivantamab, Perioperative Immunotherapy, and HER2-Targeted ADCs
• Amivantamab plus chemotherapy was approved for EGFR exon 19 deletions or exon 21 L858R substitution mutations in advanced NSCLC after progression on EGFR TKIs. • Perioperative durvalumab and nivolumab have been approved for resectable NSCLC, expanding treatment options for patients without EGFR or ALK alterations. • Fam-trastuzumab deruxtecan-nxki (T-DXd) is emerging as a significant option for HER2-mutated NSCLC, potentially shifting to frontline settings. • Ongoing research explores optimizing checkpoint inhibitor use in the perioperative setting, particularly for patients achieving complete pathologic response.